Preventing Bone Complications for Multiple Myeloma Patients
The FDA expanded the use of a molecularly targeted therapeutic to include the prevention of bone complications in patients with multiple myeloma.
Progress Against Cancer
The FDA expanded the use of a molecularly targeted therapeutic to include the prevention of bone complications in patients with multiple myeloma.
The FDA approved a molecularly targeted therapeutic for treating certain patients who have breast cancer that tests positive for a cancer-associated BRCA1 or BRCA2 mutation.
The FDA expanded the use of a targeted therapy to include certain patients with two types of non-Hodgkin lymphoma.
The FDA approved a molecularly targeted therapeutic for adults with mantle cell lymphoma that has progressed despite at least one prior treatment.
The FDA approved the second of a revolutionary new type of immunotherapy known as chimeric antigen receptor (CAR) T-cell therapy.
The FDA approved a molecularly targeted therapy for treating patients with a certain form of breast cancer.
The FDA expanded an immunotherapeutic to used for treating patients with hepatocellular carcinoma – the most common form of primary liver cancer.
The FDA expanded the use of an immunotherapeutic to include the treatment of certain patients with stomach cancer (gastric cancer).
The FDA approved a molecularly targeted therapy for treating certain adults with follicular lymphoma, a form of non-Hodgkin lymphoma.
The FDA has approved a CD22-targeted antibody-drug conjugate for treating certain adults with ALL. The U.S. Food and Drug Administration (FDA) recentlyapproved a new molecularly targeted therapeutic called inotuzumab ozogamicin (Besponsa) for treating certain...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More